Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Res Treat. 2013 Mar;45(1):74-7. doi: 10.4143/crt.2013.45.1.74. Epub 2013 Mar 31.

Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer.

Author information

1
Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea.

Abstract

Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.

KEYWORDS:

Adenocarcinoma; Drug therapy; Interstitial lung diseases; Non-small-cell lung carcinoma; Pemetrexed

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Publishing M2Community Icon for PubMed Central
    Loading ...
    Support Center